newsfilter
← Latest News
GlobeNewswire·

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ:SABS, SAB BIO)) to support the process